Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03276572 · ClinicalTrials.gov registry record · Phase 1

Phase I Trial of 225Ac-J591 in Patients With mCRPC

A Phase 1 study of Prostate Cancer, sponsored by Weill Medical College of Cornell University.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target
2
Study locations

NCT03276572 is a Phase 1 study of Prostate Cancer that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 32 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03276572, a Phase 1 study of Prostate Cancer, has completed, sponsored by Weill Medical College of Cornell University.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target
2
Study locations

Study Summary

This is an open-label, single-center Phase I dose escalation study designed to determine the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of 225Ac-J591 in a single dose regimen.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG 225Ac-J591

Study Locations (2)

Louisiana

  • Tulane Cancer Center Clinic - New Orleans

New York

  • Weill Cornell Medical College - New York

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2017-10-10
Est. Completion 2023-09-01
Phase Phase 1

Sponsor

Weill Medical College of Cornell University

701 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03276572

The ClinicalTrials.gov registry entry for NCT03276572 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which 225Ac-J591 is the first listed.

NCT03276572 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Louisiana, New York.

Frequently Asked Questions

What is clinical trial NCT03276572 about?

NCT03276572 is a clinical study titled "Phase I Trial of 225Ac-J591 in Patients With mCRPC". This is an open-label, single-center Phase I dose escalation study designed to determine the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of 225Ac-J591 in a single dose regimen.

What is the current status of trial NCT03276572?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2017-10-10. Estimated completion is 2023-09-01.

What conditions does trial NCT03276572 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT03276572?

The interventions under investigation include: 225Ac-J591 (DRUG).

Who is sponsoring clinical trial NCT03276572?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03276572 being conducted?

This trial has 2 study locations across Louisiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Louisiana

All trials with a study site in Louisiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.